Table 2.
Demographic and Clinical Characteristics of 9 Patients with Multiple Sclerosis Who Did Not Experience Clinical Nor MRI Exacerbation after Fingolimod Cessation.
| Patient No. | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 |
|---|---|---|---|---|---|---|---|---|---|
| Sex | F | F | M | F | F | M | M | F | M |
| At fingolimod initiation | |||||||||
| Disease duration (years) | 3 | 5 | 6 | 32 | 13 | 15 | 11 | 0.5 | 7 |
| ARR (preceding year) | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Clinical course | RR | RR | SP | SP | SP | RR | SP | RR | RR |
| EDSS | 1.0 | 1.5 | 5.5 | 7.0 | 4.5 | 0.0 | 6.5 | 0.0 | 0.0 |
| During fingolimod therapy | |||||||||
| Duration of fingolimod treatment (weeks) | 216 | 56 | 48 | 126 | 182 | 270 | 112 | 243 | 113 |
| ARR | 0.24 | 0 | 0 | 0.41 | 0 | 0 | 0 | 0 | 0 |
| EDSS | 1.0 | 1.5 | 5.5 | 7.0 | 4.5 | 0.0 | 7.0 | 0.0 | 0.0 |
| Age at fingolimod cessation (years) | 45 | 33 | 48 | 53 | 49 | 44 | 41 | 23 | 43 |
| Days from fingolimod cessation to DMF initiation | 77 | 42 | 35 | 41 | 43 | 72 | 34 | 34 | 30 |
| Peripheral blood lymphocyte count (/μL) | |||||||||
| At fingolimod cessation | 667 | 701 | 777 | 711 | 720 | 673 | 2,628 | 819 | 621 |
| 4 weeks after fingolimod cessation | 939 | 1,072 | 1,350 | 1,339 | 1,081 | 807 | 3,083 | 1,347 | 1,198 |
ARR: annual relapse rate, EDSS: expanded disability status scale, DMF: dimethyl fumarate, MRI: magnetic resonance imaging, RR: relapsing-remitting, SP: secondary progressive, mono: monophasic